Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
Generate Biomedicines official news-release RSS · 行业原文收录 · 来源发布：Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every six months Somerville, Mass., September 25, 2025 — Generate:Biomedicines (“Generate”) today announced that results from its Phase 1 study of GB-0895 will be presented as a late-br
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。